RYTM – rhythm pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
11/19
05:41 pm
rytm
Low
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $80.00 price target on the stock.
11/18
07:12 am
rytm
Medium
Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide [Yahoo! Finance]
11/18
07:00 am
rytm
Medium
Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide
11/13
06:36 pm
rytm
Low
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology [Yahoo! Finance]
11/13
06:30 pm
rytm
Low
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology
11/5/2024
04:01 pm
rytm
11.4%
BEAT
8/6/2024
07:00 am
rytm
0.0%
BEAT
5/7/2024
07:00 am
rytm
-11.4%
MISS
2/22/2024
07:00 am
rytm
-10.1%
IN-LINE
11/19
05:32 pm
Maintains
Buy
Buy
Canaccord Genuity
Low
-2.5%
11/6
12:55 pm
Maintains
Buy
Buy
Canaccord Genuity
Low
-0.9%
11/6
06:39 am
Maintains
Buy
Buy
Needham
High
10.3%
11/6
06:39 am
Maintains
Buy
Buy
Needham
High
10.3%
10/30
08:00 am
Reiterates
Buy
Buy
Needham & Company LLC
Medium
-3.8%
11/14
09:51 pm
rytm
Medium
Form SC 13G RHYTHM PHARMACEUTICALS, Filed by: PERCEPTIVE ADVISORS LLC
11/14
05:46 pm
rytm
Medium
Form SC 13G/A RHYTHM PHARMACEUTICALS, Filed by: RA CAPITAL MANAGEMENT, L.P.
11/13
09:05 pm
rytm
Low
Form 4 RHYTHM PHARMACEUTICALS, For: Nov 11 Filed by: Lee Jennifer Kayden
11/13
09:03 pm
rytm
Low
Form 4 RHYTHM PHARMACEUTICALS, For: Nov 11 Filed by: Shulman Joseph
11/13
09:02 pm
rytm
Low
Form 4/A RHYTHM PHARMACEUTICALS, For: Feb 09 Filed by: Shulman Joseph
Show more
Top News Gainers
8/7 Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities 14.9%
3/16 Form 4 RHYTHM PHARMACEUTICALS, For: Mar 13 Filed by: Smith Hunter C 14.5%
10/15 Form 8-K RHYTHM PHARMACEUTICALS, For: Oct 15 13.4%
10/18 Form 3 RHYTHM PHARMACEUTICALS, For: Oct 16 Filed by: RA Capital Healthcare Fund LP 10.2%
4/9 Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 10.0%
11/22 Form 4 RHYTHM PHARMACEUTICALS, For: Nov 20 Filed by: Foley Todd 6.3%
3/2 Q4/2019 12/31/2019 EPS -0.780 ZacksConsensus N/A ActVsEst N/A - N/A 6.2%
12/5 Rhythm Pharmaceuticals Completes Enrollment of Pivotal Cohort in Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes 6.0%
2/25 Rhythm Pharmaceuticals to Present at Cowen & Co. 40th Annual Health Care Conference 5.5%
3/30 Rhythm Pharmaceuticals Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Setmelanotide in POMC and LEPR Deficiency Obesities 5.1%
Top News Decliners
8/7 Form 8-K RHYTHM PHARMACEUTICALS, For: Aug 07 -9.8%
9/25 Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $40.00 price target on the stock. -8.5%
1/10 Form 8-K RHYTHM PHARMACEUTICALS, For: Jan 10 -5.1%
2/26 Form 8-K RHYTHM PHARMACEUTICALS, For: Feb 20 -5.0%
4/30 Form 4 RHYTHM PHARMACEUTICALS, For: Apr 28 Filed by: Foley Todd -4.7%
4/29 Form DEF 14A RHYTHM PHARMACEUTICALS, For: Jun 17 -4.7%
3/18 Rhythm Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for Setmelanotide for the Treatment of Alström Syndrome -4.6%
7/29 Rhythm Pharmaceuticals Reports Second Quarter 2019 Financial Results -4.2%
6/21 Form 3 RHYTHM PHARMACEUTICALS, For: Jun 19 Filed by: GOOD JENNIFER L -4.1%
1/6 Rhythm Pharmaceuticals Announces Leadership Transition -4.1%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3